about
Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party.The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survivalSNP rs6457327 in the HLA region on chromosome 6p is predictive of the transformation of follicular lymphoma.Functional analysis of a breast cancer-associated FGFR2 single nucleotide polymorphism using zinc finger mediated genome editing.MicroRNA profiles of t(14;18)-negative follicular lymphoma support a late germinal center B-cell phenotype.High Throughput Sequencing Analysis of the Immunoglobulin Heavy Chain Gene from Flow-Sorted B Cell Sub-Populations Define the Dynamics of Follicular Lymphoma Clonal Evolution.Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms.Familial myelodysplasia and acute myeloid leukaemia--a review.TNFRSF14 aberrations in follicular lymphoma increase clinically significant allogeneic T-cell responses.Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformationEZH2 mutations are frequent and represent an early event in follicular lymphoma.Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterationsIntegrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma.Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma.The clinical relevance of Wilms Tumour 1 (WT1) gene mutations in acute leukaemia.Molecular signatures in the diagnosis and management of follicular lymphoma.Transformation of indolent B-cell lymphomas.Epigenetic dysregulation in follicular lymphoma.Reduced Expression of Histone Methyltransferases KMT2C and KMT2D Correlates with Improved Outcome in Pancreatic Ductal AdenocarcinomaThe routes for transformation of follicular lymphoma.Advances in the molecular diagnosis of diffuse large B-cell lymphoma in the era of precision medicine.Follicular lymphoma: State-of-the-art ICML workshop in Lugano 2015.Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma.Familial CEBPA-mutated acute myeloid leukemia.AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo.Chemosensitization of B-cell lymphomas by methylseleninic acid involves nuclear factor-kappaB inhibition and the rapid generation of other selenium species.Disease evolution and outcomes in familial AML with germline CEBPA mutations.Clinical utility gene card for: Familial platelet disorder with associated myeloid malignanciesMutations of the PU.1 Ets domain are specifically associated with murine radiation-induced, but not human therapy-related, acute myeloid leukaemia.Clinical relevance of MDM2 SNP 309 and TP53 Arg72Pro in follicular lymphoma.Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2.Presentation serum selenium predicts for overall survival, dose delivery, and first treatment response in aggressive non-Hodgkin's lymphoma.Genomic analysis reveals epigenetic ‘addiction’ underpinning follicular lymphoma and its transformation – a rationale for targeted epigenetic therapies.The co-receptor BTLA negatively regulates human Vγ9Vδ2 T-cell proliferation: a potential way of immune escape for lymphoma cells.A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy.Myeloblative therapy with autologous haematopoietic stem cell support as consolidation of first remission in acute myeloid leukaemia - very long follow-up.GATA2 mutations in sporadic and familial acute myeloid leukaemia patients with CEBPA mutations.Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone.Development of a quantitative real-time polymerase chain reaction method for monitoring CEBPA mutations in normal karyotype acute myeloid leukaemia.Inherited DDX41 mutations: 11 genes and counting.
P50
Q27851437-02B8F85A-6CC9-452D-9B3D-1DB5A930F28CQ34198023-1C71E8B0-2BCF-4B94-B1C1-FF8FCC3FEE5DQ34707259-B7DDED2C-86C8-4833-9616-89690A73A468Q35050363-7CAD66CE-1AE7-445E-A60B-2C7EB6E172FDQ35553338-6D2A8DE1-A79F-44FA-8F7A-E37E0A2365A7Q35760980-A0C917C5-FBC9-4F10-8683-69686F21C289Q36869113-626E97B6-8234-4AA3-A2A2-0E2A817C8069Q37049532-EEA740FF-E349-46D7-A753-2137F03CF645Q37116255-C0A1AB50-473C-40B3-B5D7-2B7E96E963D4Q37119935-3EA562A0-59FE-4694-8DB3-1AC8A67697F5Q37272035-9E1A1D96-68DF-4F60-98AB-5E101101F65CQ37275890-1CB1EE9B-7BE6-4B66-B007-28F119E2AB14Q37533656-4979E5F7-0C1E-41FA-9512-0DC84A836326Q37636972-BE7196FA-1683-49BF-8F8A-3B18035A0FB1Q37655886-9BEC214D-349F-4560-BF7A-38C533453A75Q37767122-7C8DE84D-1F1F-4030-8075-F39D005D4449Q37863999-6777C5B1-E4C2-4FF1-8884-37A9E3C0ED1DQ38677466-DAA668A3-D8C8-4C98-BC35-DAEA9802C4B8Q38765519-74A57807-2D6A-478E-B113-3378E5D8F59BQ38823042-574FFAA0-7F58-4CE3-B3F5-9C52CFDC7ABBQ38959472-B248BFD1-B764-4DC5-8B24-A4EA8EECD9A1Q39221094-DB7F46C7-E8F4-4781-8F47-BE9BF3FF543BQ39349837-0030FEA7-A265-42D9-8BA0-98475341230FQ39388791-10997BD1-0F99-426B-88DC-689188DBABF6Q39861028-9D608250-3F2C-4960-9698-41A521A3EE04Q40050548-3A96495C-485C-4837-8DA4-AC76DF5E385DQ40750784-96BCE712-E197-417E-B224-9615A10C24CAQ42385930-C47DE396-068B-49F8-824C-FB2D786A8BCFQ42801824-DE7F606A-91D5-4F76-9B2A-5C31349CB69AQ43199551-0879736E-CE46-4CE5-B5B7-AA396286F4B3Q44379467-ADD13592-C8DA-44C7-8F82-1F759F7F83E9Q44477267-F4FB0A7D-82EF-4BF0-8CB4-47DE25FA3469Q45769828-E2811F6A-BAF9-4B65-8FD7-9F2AA79B932DQ45950820-5C62B804-FE24-4F2F-B6EF-A5325E767561Q46719897-2ABB7821-B570-406F-B16D-56B786E49050Q47619423-B71D9EA2-AC38-4EB4-94B6-B22C967409DEQ50482088-C130F88A-E902-4E42-9D89-788C7B329FB8Q53313067-53A9C51D-33CC-4E2E-8278-D409D70D5326Q54615564-07A931AF-1521-403F-BBA7-DAA4A58F885FQ55029291-CB5B06E0-6EBC-47BD-80A3-B1EEEAC44030
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Jude Fitzgibbon
@ast
Jude Fitzgibbon
@en
Jude Fitzgibbon
@es
Jude Fitzgibbon
@nl
type
label
Jude Fitzgibbon
@ast
Jude Fitzgibbon
@en
Jude Fitzgibbon
@es
Jude Fitzgibbon
@nl
prefLabel
Jude Fitzgibbon
@ast
Jude Fitzgibbon
@en
Jude Fitzgibbon
@es
Jude Fitzgibbon
@nl
P106
P21
P31
P496
0000-0002-9069-1866